A clinical trial involving terlipressin was registered on August 18, 2026. The study, titled "Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Upper Gastrointestinal Bleeding and Renal Dysfunction," is listed under identifier NCT07252401.
The trial's current status is not yet recruiting. No phase designation has been assigned, as the listing indicates phase NA.
The study aims to compare terlipressin with somatostatin in a population of cirrhotic patients presenting with acute upper gastrointestinal bleeding alongside renal dysfunction. As the trial has not yet begun recruiting participants, no outcomes or results are currently available.
Terlipressin is an approved compound. This registration reflects the initiation of a planned comparative study and does not represent completed research or reported findings.
Further details on the trial's design, timeline, and eligibility criteria may become available as the study progresses toward recruitment. Readers interested in the background and general profile of terlipressin can consult the compound overview for additional context.